Globeflex Capital L P Sells 5,186 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Globeflex Capital L P cut its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 8.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 54,858 shares of the biotechnology company's stock after selling 5,186 shares during the quarter. United Therapeutics makes up 1.6% of Globeflex Capital L P's investment portfolio, making the stock its 13th largest holding. Globeflex Capital L P owned 0.12% of United Therapeutics worth $19,356,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Newbridge Financial Services Group Inc. purchased a new stake in shares of United Therapeutics during the 4th quarter valued at $25,000. Brooklyn Investment Group purchased a new stake in United Therapeutics in the 3rd quarter worth about $33,000. MassMutual Private Wealth & Trust FSB increased its holdings in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 58 shares during the last quarter. Jones Financial Companies Lllp increased its holdings in United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after acquiring an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in United Therapeutics in the 4th quarter worth about $131,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on UTHR. UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. StockNews.com lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. Finally, HC Wainwright reissued a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $388.25.

Remove Ads

Insider Activity

In other news, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the sale, the director now owns 5,051 shares in the company, valued at approximately $1,885,134.22. This trade represents a 83.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the sale, the director now owns 5,528 shares of the company's stock, valued at approximately $1,966,696.56. This trade represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 116,464 shares of company stock worth $42,396,244. 11.90% of the stock is currently owned by insiders.

United Therapeutics Price Performance

UTHR stock traded down $8.82 during mid-day trading on Tuesday, reaching $314.12. 417,946 shares of the company traded hands, compared to its average volume of 443,773. The company has a market capitalization of $14.11 billion, a P/E ratio of 13.80, a P/E/G ratio of 0.97 and a beta of 0.64. The company has a fifty day moving average price of $348.15 and a 200-day moving average price of $357.92. United Therapeutics Co. has a 52-week low of $221.53 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter last year, the company posted $4.36 EPS. As a group, analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.